恒瑞医药SHR-2906注射液临床试验获批

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-2906 injection, aimed at treating overweight or obesity [1] Group 1: Product Development - SHR-2906 injection is a self-developed biological product by Heng Rui Medicine, expected to have a synergistic effect in reducing energy intake and promoting energy expenditure, thereby regulating glucose and lipid metabolism and controlling weight [1] - The product aims to improve the metabolic environment within the body, potentially demonstrating clinical efficacy in treating overweight and obesity [1]